Australian researchers spearhead paradigm shift in melanoma treatment

Australian researchers spearhead paradigm shift in melanoma treatment

20 September 2021

In what has been described as a paradigm shift in the treatment of melanoma, drug therapy looks set to become the standard treatment for high-risk early stage melanoma patients to stop disease spread and save lives.

Promising results from an international multi-centre clinical trial, which included researchers and patients from Melanoma Institute Australia (MIA), were presented this weekend at the prestigious European Society for Medical Oncology (ESMO) Congress.

Results showed giving high-risk Stage II melanoma patients the same immunotherapy drugs approved for use in advanced melanoma patients, reduced the risk of their disease returning or death by 35%.

Study author Professor Georgina Long AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, said the findings would result in a paradigm shift in treatment of early stage patients.

‘We are using drug therapy already proven to be life-saving for advanced melanoma patients, to stop the disease in its tracks in earlier stage patients,’ Professor Long said. ‘These exciting clinical trial results are strong evidence to support approval for this immunotherapy to become standard treatment for high-risk  Stage II patients in Australia.’

The clinical trial demonstrated that giving pembrolizumab (Keytruda™) after surgery to patients with Stage IIB or IIC melanoma (deemed at high risk of spread due to tumour thickness or ulceration) reduced the risk of the disease returning or death by 35% compared to placebo. At 12 months, only 9.5% of patients on pembrolizumab had their melanoma progress, compared to 16.9% in the placebo group.

In the last decade, the approval of immunotherapy for Stage III and IV melanoma patients has dramatically increased survival rates, with more than 50% of these patients now essentially cured.

However, there are no immunotherapy drugs currently approved for use in Stage II melanoma patients. They instead have to adopt a ‘watch-and-wait’ approach after surgery to see if their cancer will return or spread. Patients with thick Stage II melanoma also often undergo an invasive Sentinel Node Biopsy to check for disease spread, with drug therapy only available once their disease has spread to their lymph nodes (Stage III).

Fellow study author Professor Richard Scolyer AO, Co-Medical Director of Melanoma Institute Australia and of The University of Sydney, says the clinical trial results stand to transform how earlier stage disease is managed.

‘By giving this immunotherapy treatment at an earlier stage, we are proactively preventing melanoma spread,’ Professor Scolyer said.

Australia has the highest melanoma rates in the world with one person diagnosed with the disease every 30 minutes. An estimated 1300 Australians are expected to die from melanoma this year.

Following these clinical trial results, it is hoped pembrolizumab will soon come before the Pharmaceutical Benefits Advisory Committee (PBAC) for approval for use in these patients in Australia.

‘This proactive approach to preventing disease spread represents a significant step forward in our mission of reaching zero deaths from melanoma,’ Professor Scolyer added.

___________________________________________________________________________

The full data set was presented at ESMO on Saturday 18 September 2021 at 11:05pm (AEST) by Associate Professor Jason Luke in a presentation entitled: “Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the Keynote 716 double-blinded phase III trial”.
Melanoma Institute Australia is affiliated with The University of Sydney and Professor Scolyer and Professor Long lead the Translational Research Group at the Charles Perkins Centre.
 

Media contact:

Jennifer Durante |media@melanoma.org.au | 0412 798 990

Journalist and news reader Peter Overton our new National Ambassador
23 Nov 2021

Journalist and news reader Peter Overton our new National Ambassador

Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
19 Nov 2021

MIA researchers feature on prestigious Highly Cited Researchers 2021 List

MIA is proud to announce that five of our researchers have been named on the annual Highly Cited Researchers™ 2021 list from Clarivate.

Tags: melanoma
New research into importance of skin surveillance to save lives from melanoma
04 Nov 2021

New research into importance of skin surveillance to save lives from melanoma

New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.

Tags: melanoma
Game On Mole - saving lives this summer
31 Oct 2021

Game On Mole - saving lives this summer

With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever. 

Tags: melanoma
Melanoma March physical events in 2022
22 Oct 2021

Melanoma March physical events in 2022

We are excited to announce a return to our much-loved physical Melanoma March events in March 2022! 

Tags: melanoma
Community Fundraising Wrap Up July-Sept 2021
15 Oct 2021

Community Fundraising Wrap Up July-Sept 2021

Read more about the wonderful MIA community fundraising initiatives held recently.

Tags: melanoma
Australian researchers spearhead paradigm shift in melanoma treatment
20 Sep 2021

Australian researchers spearhead paradigm shift in melanoma treatment

Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread

Tags: melanoma
Melanoma Bike Bash 2021: What a ride!
20 Sep 2021

Melanoma Bike Bash 2021: What a ride!

Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!

Tags: melanoma
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
16 Sep 2021

Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS

Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.

Tags: melanoma
MIA researchers awarded $7.2m in NHMRC grants for health research
15 Sep 2021

MIA researchers awarded $7.2m in NHMRC grants for health research

Three MIA researchers at University of Sydney received grants to further their important melanoma research.

Tags: melanoma
Amie St Clair Ball in Wagga postponed for a third time
06 Sep 2021

Amie St Clair Ball in Wagga postponed for a third time

COVID restrictions continue to impact fundraising for melanoma services in Riverina.

Honouring Ben's life by supporting the next generation of melanoma researchers
30 Aug 2021

Honouring Ben's life by supporting the next generation of melanoma researchers

Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.

MIA's annual Research Retreat 2021
20 Aug 2021

MIA's annual Research Retreat 2021

More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.

Understanding the needs of Stage III melanoma patients when choosing treatments.
28 Jul 2021

Understanding the needs of Stage III melanoma patients when choosing treatments.

Independent researchers at The University of Sydney are seeking patient feedback.

Community Fundraising Wrap Up Apr-June 2021
21 Jul 2021

Community Fundraising Wrap Up Apr-June 2021

A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.

Tags: melanoma
Patients paying it forward
19 Jul 2021

Patients paying it forward

Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients. 

Tags: melanoma
Research boost to improve outcomes for melanoma patients
15 Jul 2021

Research boost to improve outcomes for melanoma patients

MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.

Tags: melanoma
Amie St Clair 10th Annual Ball
25 Jun 2022

Amie St Clair 10th Annual Ball

Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!   

Riverina Melanoma Ride
31 Mar - 07 Apr 2022

Riverina Melanoma Ride

Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!